SCHEMBL25613142

SCHEMBL25613142

CC(C)(C)c1cc2cc[nH]c2nc1CC1CCOC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 4/20 0.38
▸ MTOR P42345 3/20 0.38
▸ PIK3CD O00329 2/20 0.38
▸ JAK1 P23458 2/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ TYK2 P29597 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ GRM4 Q14833 1/20 0.33
▸ ULK1 O75385 3/20 0.31
▸ IRAK4 Q9NWZ3 1/20 0.31
▸ NLRP3 Q96P20 1/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ SCN8A Q9UQD0 1/20 0.31
▸ PARP1 P09874 1/20 0.30
▸ IRAK1 P51617 1/20 0.30
▸ PDE3B Q13370 1/20 0.30
▸ PDE3A Q14432 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613150 0.90 ULK1 (0.31) PIK3CAMTORPIK3CDULK1
SCHEMBL25613146 0.81 CACNA1G (0.34) SLC6A2SLC6A4SLC6A3
SCHEMBL25627935 0.81 PIK3CA (0.31) PIK3CAMTORPIK3CD
SCHEMBL24005771 0.81 PIK3CA (0.38) PIK3CAMTORPIK3CDJAK1JAK2
SCHEMBL25613162 0.80 HRH4 (0.37) SLC6A2SLC6A4SLC6A3
SCHEMBL25613088 0.74 GRM4 (0.40) PIK3CAMTORPIK3CDJAK1JAK2
SCHEMBL25613081 0.74 LRRK2 (0.41) GRM4
SCHEMBL19367958 0.73 FEN1 (0.36) PIK3CAPIK3CDULK1
SCHEMBL25613160 0.73 ALOX15 (0.41) PIK3CAMTORJAK2
SCHEMBL24005769 0.73 PIK3CA (0.36) PIK3CAMTORPIK3CDJAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 PIK3CA 1141/4885MTOR 964/4885PIK3CD 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback